Drug Facts
Composition & Profile
Identifiers & Packaging
HOW SUPPLIED ATROPINE SULFATE INJECTION, USP is supplied in the following dosage forms: NDC 51662-1311-1 ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL NDC 51662-1311-2 - 1 Pouch of ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL NDC 51662-1311-3 - Case of 25 pouches of ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL HF Acquisition Co LLC, DBA HealthFirst Mukilteo, WA 98275 Also supplied in the following manufacture supplied dosage forms Atropine Sulfate Injection, USP is available in the following: 0.4 mg/mL 20 mL multiple dose vial packaged in 10s (NDC 0641-6006-10) Use only if solution is clear and seal intact. Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: WEST-WARD PHARMACEUTICALS Eatontown, NJ 07724 USA Revised June 2011 462-416-01 LOGO; PRINCIPAL DISPLAY PANEL, VIAL NDC 0641-6006-01 Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) 20 mL Multiple Dose Vial NDC 0641-6006-01 VIAL; PRINCIPAL DISPLAY PANEL, NDC 51662-1311-1 SERIALIZED VIAL SERIALIZED VIAL; PRINCIPAL DISPLAY LABEL - NDC 51662-1311-2 SERIALIZED POUCH LABEL SERIALIZED POUCH LABEL; PRINCIPAL DISPLAY LABEL - NDC 51662-1311-3 SERIALIZED CASE LABEL case; PRINCIPAL DISPLAY LABEL - NDC 51662-1311-3 SERIALIZED RFID LABEL Serialized RFID
- HOW SUPPLIED ATROPINE SULFATE INJECTION, USP is supplied in the following dosage forms: NDC 51662-1311-1 ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL NDC 51662-1311-2 - 1 Pouch of ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL NDC 51662-1311-3 - Case of 25 pouches of ATROPINE SULFATE INJECTION, USP 8mg/20mL (0.4mg/mL) 20mL VIAL HF Acquisition Co LLC, DBA HealthFirst Mukilteo, WA 98275 Also supplied in the following manufacture supplied dosage forms Atropine Sulfate Injection, USP is available in the following: 0.4 mg/mL 20 mL multiple dose vial packaged in 10s (NDC 0641-6006-10) Use only if solution is clear and seal intact. Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceutical Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: WEST-WARD PHARMACEUTICALS Eatontown, NJ 07724 USA Revised June 2011 462-416-01 LOGO
- PRINCIPAL DISPLAY PANEL, VIAL NDC 0641-6006-01 Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL) 20 mL Multiple Dose Vial NDC 0641-6006-01 VIAL
- PRINCIPAL DISPLAY PANEL, NDC 51662-1311-1 SERIALIZED VIAL SERIALIZED VIAL
- PRINCIPAL DISPLAY LABEL - NDC 51662-1311-2 SERIALIZED POUCH LABEL SERIALIZED POUCH LABEL
- PRINCIPAL DISPLAY LABEL - NDC 51662-1311-3 SERIALIZED CASE LABEL case
- PRINCIPAL DISPLAY LABEL - NDC 51662-1311-3 SERIALIZED RFID LABEL Serialized RFID
Overview
Atropine Sulfate Injection, USP is a sterile solution of atropine sulfate in Water for Injection. Each mL contains Atropine Sulfate 0.4 mg; Sodium Chloride 9 mg; Benzyl Alcohol 9 mg; Water for Injection qs; pH may be adjusted with Sulfuric Acid if necessary. pH 3.0-6.5. Atropine Sulfate Injection, USP may be given intramuscularly, intravenously or subcutaneously. Atropine is a white crystalline alkaloid which may be extracted from belladonna root or may be produced synthetically. It is used as atropine sulfate because this compound has much greater solubility. Atropine sulfate is an anticholinergic drug. The empirical formula of atropine sulfate is (C17H23NO3)2•H2SO4•H2O. The structural formula is: STRUCTURE
Indications & Usage
INDICATIONS & USAGE Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations.
Dosage & Administration
DOSAGE & ADMINISTRATION The usual dose of atropine sulfate is 0.4 to 0.6 mg. Suggested dosages for pediatric patients are as follows: 7 - 16 lbs. – 0.1 mg 40 - 65 lbs. – 0.3 mg 17 - 24 lbs. – 0.15 mg 65 - 90 lbs. – 0.4 mg 24 - 40 lbs. – 0.2 mg Over 90 lbs. – 0.4 to 0.6 mg Table of Dosage Equivalents These doses may be exceeded in certain cases. For hypotonic radiography of the gastrointestinal tract, the usual adult dose is 1 mg intramuscularly. Adults suspected of contact with organic phosporous insecticides of the parathion type should be given atropine sulfate 0.8 mg intramuscularly. If an atropine effect is not apparent within 30 minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements and excessive sweating, salivation and bronchial secretion), atropine sulfate 2 mg should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to 2 or 3 times of this dose (4 to 6 mg) may be required in severe cases. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. DOSAGE
Warnings & Precautions
WARNINGS Atropine is a highly potent drug and due care is essential to avoid overdosage, especially with intravenous administration. Pediatric populations are more susceptible than adults to the toxic effects of anticholinergic agents. Atropine I.V. decreased the rate of mexiletine absorption without altering the relative oral bioavailability; this delay in mexiletine absorption was reversed by the combination of atropine and intravenous metoclopramide during pretreatment for anesthesia. Atropine is not removed by dialysis. This drug is effective in very low dosage and overdose may cause permanent damage or death, especially in children. This product contains Benzyl Alcohol which has been associated with a fatal gasping syndrome in infants and neonates.
Contraindications
Conditions at which inhibition of postganglionic cholinergic nerves are undesirable, such as glaucoma and tachycardia. Also contraindicated in asthma, because the parenteral dose which might relieve asthma would have an excessive drying effect upon mucous plugs in the bronchi. Prostatic hypertrophy, while not a contraindication, requires special attention to signs of urinary retention.
Adverse Reactions
Individual tolerance varies greatly, but these systemic doses are likely to produce the following effects: A scarlatiniform rash may occur. Atropine may produce fever, particularly in children, through inhibition of heat loss by evaporation. Although large doses of atropine may cause an alarming condition, recovery is usual. ADVERSE EVENT TABEL
Similar Drugs
Related medications based on brand, generic name, substance, active ingredients.